Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-02-17

Clinical Trial Update: PK, PD, Safety, and Efficacy of SAIT101 Versus MabThera® Versus Rituxan® in Patients With Rheumatoid Arthritis [Phase 1]

View source ↗

Summary

Phase 1 trial comparing SAIT101 with MabThera/Rituxan in rheumatoid arthritis completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • MabThera (rituximab)
  • Rituxan (rituximab)
  • SAIT101

Snippet

Sponsor: Archigen Biotech Limited | Conditions: Rheumatoid Arthritis | Phase 1 | Status: COMPLETED | Results posted: 2020-02-17